Enterprise Value

2.457B

Cash

42.11M

Avg Qtr Burn

-8.319M

Short % of Float

0.91%

Insider Ownership

0.51%

Institutional Own.

61.37%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Setrusumab (UX143) Details
Osteogenesis imperfecta

Phase 2/3

Data readout

Phase 2

Data readout

Phase 2

Data readout

Etigilimab Details
Ovarian cancer

Phase 1b

Update

Phase 1b

Update

Failed

Discontinued